Global Insulin Biosimilars Supply, Demand and Key Producers, 2023-2029

Page: 111

Published Date: 01 Feb 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The global Insulin Biosimilars market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Biosimilar insulin is likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulin has the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes.

This report studies the global Insulin Biosimilars production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Insulin Biosimilars, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Insulin Biosimilars that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Insulin Biosimilars total production and demand, 2018-2029, (K Units)
Global Insulin Biosimilars total production value, 2018-2029, (USD Million)
Global Insulin Biosimilars production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Insulin Biosimilars consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Insulin Biosimilars domestic production, consumption, key domestic manufacturers and share
Global Insulin Biosimilars production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Insulin Biosimilars production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Insulin Biosimilars production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Insulin Biosimilars market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi S.A., Boehringer Ingelheim, Eli Lilly & Co., Novo Nordisk A/S, Biocon, Geropharm, Wockhardt, Gan&Lee Pharmaceuticals and The United Laboratories International, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Insulin Biosimilars market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (USD/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Insulin Biosimilars Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Insulin Biosimilars Market, Segmentation by Type
    Rapid-Acting Biosimilars
    Long-Acting Biosimilars
    Premixed Biosimilars

Global Insulin Biosimilars Market, Segmentation by Application
    Type I Diabetes
    Type II Diabetes

Companies Profiled:
    Sanofi S.A.
    Boehringer Ingelheim
    Eli Lilly & Co.
    Novo Nordisk A/S
    Biocon
    Geropharm
    Wockhardt
    Gan&Lee Pharmaceuticals
    The United Laboratories International
    Tonghua Dongbao Pharmaceutical

Key Questions Answered
1. How big is the global Insulin Biosimilars market?
2. What is the demand of the global Insulin Biosimilars market?
3. What is the year over year growth of the global Insulin Biosimilars market?
4. What is the production and production value of the global Insulin Biosimilars market?
5. Who are the key producers in the global Insulin Biosimilars market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Insulin Biosimilars Introduction
    1.2 World Insulin Biosimilars Supply & Forecast
        1.2.1 World Insulin Biosimilars Production Value (2018 & 2022 & 2029)
        1.2.2 World Insulin Biosimilars Production (2018-2029)
        1.2.3 World Insulin Biosimilars Pricing Trends (2018-2029)
    1.3 World Insulin Biosimilars Production by Region (Based on Production Site)
        1.3.1 World Insulin Biosimilars Production Value by Region (2018-2029)
        1.3.2 World Insulin Biosimilars Production by Region (2018-2029)
        1.3.3 World Insulin Biosimilars Average Price by Region (2018-2029)
        1.3.4 North America Insulin Biosimilars Production (2018-2029)
        1.3.5 Europe Insulin Biosimilars Production (2018-2029)
        1.3.6 China Insulin Biosimilars Production (2018-2029)
        1.3.7 Japan Insulin Biosimilars Production (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Insulin Biosimilars Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Insulin Biosimilars Major Market Trends
    1.5 Influence of COVID-19 and Russia-Ukraine War
        1.5.1 Influence of COVID-19
        1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
    2.1 World Insulin Biosimilars Demand (2018-2029)
    2.2 World Insulin Biosimilars Consumption by Region
        2.2.1 World Insulin Biosimilars Consumption by Region (2018-2023)
        2.2.2 World Insulin Biosimilars Consumption Forecast by Region (2024-2029)
    2.3 United States Insulin Biosimilars Consumption (2018-2029)
    2.4 China Insulin Biosimilars Consumption (2018-2029)
    2.5 Europe Insulin Biosimilars Consumption (2018-2029)
    2.6 Japan Insulin Biosimilars Consumption (2018-2029)
    2.7 South Korea Insulin Biosimilars Consumption (2018-2029)
    2.8 ASEAN Insulin Biosimilars Consumption (2018-2029)
    2.9 India Insulin Biosimilars Consumption (2018-2029)

3 World Insulin Biosimilars Manufacturers Competitive Analysis
    3.1 World Insulin Biosimilars Production Value by Manufacturer (2018-2023)
    3.2 World Insulin Biosimilars Production by Manufacturer (2018-2023)
    3.3 World Insulin Biosimilars Average Price by Manufacturer (2018-2023)
    3.4 Insulin Biosimilars Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Insulin Biosimilars Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Insulin Biosimilars in 2022
        3.5.3 Global Concentration Ratios (CR8) for Insulin Biosimilars in 2022
    3.6 Insulin Biosimilars Market: Overall Company Footprint Analysis
        3.6.1 Insulin Biosimilars Market: Region Footprint
        3.6.2 Insulin Biosimilars Market: Company Product Type Footprint
        3.6.3 Insulin Biosimilars Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Insulin Biosimilars Production Value Comparison
        4.1.1 United States VS China: Insulin Biosimilars Production Value Comparison (2018 & 2022 & 2029)
        4.1.2 United States VS China: Insulin Biosimilars Production Value Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States VS China: Insulin Biosimilars Production Comparison
        4.2.1 United States VS China: Insulin Biosimilars Production Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Insulin Biosimilars Production Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States VS China: Insulin Biosimilars Consumption Comparison
        4.3.1 United States VS China: Insulin Biosimilars Consumption Comparison (2018 & 2022 & 2029)
        4.3.2 United States VS China: Insulin Biosimilars Consumption Market Share Comparison (2018 & 2022 & 2029)
    4.4 United States Based Insulin Biosimilars Manufacturers and Market Share, 2018-2023
        4.4.1 United States Based Insulin Biosimilars Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Insulin Biosimilars Production Value (2018-2023)
        4.4.3 United States Based Manufacturers Insulin Biosimilars Production (2018-2023)
    4.5 China Based Insulin Biosimilars Manufacturers and Market Share
        4.5.1 China Based Insulin Biosimilars Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Insulin Biosimilars Production Value (2018-2023)
        4.5.3 China Based Manufacturers Insulin Biosimilars Production (2018-2023)
    4.6 Rest of World Based Insulin Biosimilars Manufacturers and Market Share, 2018-2023
        4.6.1 Rest of World Based Insulin Biosimilars Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Insulin Biosimilars Production Value (2018-2023)
        4.6.3 Rest of World Based Manufacturers Insulin Biosimilars Production (2018-2023)

5 Market Analysis by Type
    5.1 World Insulin Biosimilars Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Rapid-Acting Biosimilars
        5.2.2 Long-Acting Biosimilars
        5.2.3 Premixed Biosimilars
    5.3 Market Segment by Type
        5.3.1 World Insulin Biosimilars Production by Type (2018-2029)
        5.3.2 World Insulin Biosimilars Production Value by Type (2018-2029)
        5.3.3 World Insulin Biosimilars Average Price by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Insulin Biosimilars Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Type I Diabetes
        6.2.2 Type II Diabetes
    6.3 Market Segment by Application
        6.3.1 World Insulin Biosimilars Production by Application (2018-2029)
        6.3.2 World Insulin Biosimilars Production Value by Application (2018-2029)
        6.3.3 World Insulin Biosimilars Average Price by Application (2018-2029)

7 Company Profiles
    7.1 Sanofi S.A.
        7.1.1 Sanofi S.A. Details
        7.1.2 Sanofi S.A. Major Business
        7.1.3 Sanofi S.A. Insulin Biosimilars Product and Services
        7.1.4 Sanofi S.A. Insulin Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.1.5 Sanofi S.A. Recent Developments/Updates
        7.1.6 Sanofi S.A. Competitive Strengths & Weaknesses
    7.2 Boehringer Ingelheim
        7.2.1 Boehringer Ingelheim Details
        7.2.2 Boehringer Ingelheim Major Business
        7.2.3 Boehringer Ingelheim Insulin Biosimilars Product and Services
        7.2.4 Boehringer Ingelheim Insulin Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.2.5 Boehringer Ingelheim Recent Developments/Updates
        7.2.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
    7.3 Eli Lilly & Co.
        7.3.1 Eli Lilly & Co. Details
        7.3.2 Eli Lilly & Co. Major Business
        7.3.3 Eli Lilly & Co. Insulin Biosimilars Product and Services
        7.3.4 Eli Lilly & Co. Insulin Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.3.5 Eli Lilly & Co. Recent Developments/Updates
        7.3.6 Eli Lilly & Co. Competitive Strengths & Weaknesses
    7.4 Novo Nordisk A/S
        7.4.1 Novo Nordisk A/S Details
        7.4.2 Novo Nordisk A/S Major Business
        7.4.3 Novo Nordisk A/S Insulin Biosimilars Product and Services
        7.4.4 Novo Nordisk A/S Insulin Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.4.5 Novo Nordisk A/S Recent Developments/Updates
        7.4.6 Novo Nordisk A/S Competitive Strengths & Weaknesses
    7.5 Biocon
        7.5.1 Biocon Details
        7.5.2 Biocon Major Business
        7.5.3 Biocon Insulin Biosimilars Product and Services
        7.5.4 Biocon Insulin Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.5.5 Biocon Recent Developments/Updates
        7.5.6 Biocon Competitive Strengths & Weaknesses
    7.6 Geropharm
        7.6.1 Geropharm Details
        7.6.2 Geropharm Major Business
        7.6.3 Geropharm Insulin Biosimilars Product and Services
        7.6.4 Geropharm Insulin Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.6.5 Geropharm Recent Developments/Updates
        7.6.6 Geropharm Competitive Strengths & Weaknesses
    7.7 Wockhardt
        7.7.1 Wockhardt Details
        7.7.2 Wockhardt Major Business
        7.7.3 Wockhardt Insulin Biosimilars Product and Services
        7.7.4 Wockhardt Insulin Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.7.5 Wockhardt Recent Developments/Updates
        7.7.6 Wockhardt Competitive Strengths & Weaknesses
    7.8 Gan&Lee Pharmaceuticals
        7.8.1 Gan&Lee Pharmaceuticals Details
        7.8.2 Gan&Lee Pharmaceuticals Major Business
        7.8.3 Gan&Lee Pharmaceuticals Insulin Biosimilars Product and Services
        7.8.4 Gan&Lee Pharmaceuticals Insulin Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.8.5 Gan&Lee Pharmaceuticals Recent Developments/Updates
        7.8.6 Gan&Lee Pharmaceuticals Competitive Strengths & Weaknesses
    7.9 The United Laboratories International
        7.9.1 The United Laboratories International Details
        7.9.2 The United Laboratories International Major Business
        7.9.3 The United Laboratories International Insulin Biosimilars Product and Services
        7.9.4 The United Laboratories International Insulin Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.9.5 The United Laboratories International Recent Developments/Updates
        7.9.6 The United Laboratories International Competitive Strengths & Weaknesses
    7.10 Tonghua Dongbao Pharmaceutical
        7.10.1 Tonghua Dongbao Pharmaceutical Details
        7.10.2 Tonghua Dongbao Pharmaceutical Major Business
        7.10.3 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product and Services
        7.10.4 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.10.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates
        7.10.6 Tonghua Dongbao Pharmaceutical Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Insulin Biosimilars Industry Chain
    8.2 Insulin Biosimilars Upstream Analysis
        8.2.1 Insulin Biosimilars Core Raw Materials
        8.2.2 Main Manufacturers of Insulin Biosimilars Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Insulin Biosimilars Production Mode
    8.6 Insulin Biosimilars Procurement Model
    8.7 Insulin Biosimilars Industry Sales Model and Sales Channels
        8.7.1 Insulin Biosimilars Sales Model
        8.7.2 Insulin Biosimilars Typical Customers

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Insulin Biosimilars Production Value by Region (2018, 2022 and 2029) & (USD Million)
    Table 2. World Insulin Biosimilars Production Value by Region (2018-2023) & (USD Million)
    Table 3. World Insulin Biosimilars Production Value by Region (2024-2029) & (USD Million)
    Table 4. World Insulin Biosimilars Production Value Market Share by Region (2018-2023)
    Table 5. World Insulin Biosimilars Production Value Market Share by Region (2024-2029)
    Table 6. World Insulin Biosimilars Production by Region (2018-2023) & (K Units)
    Table 7. World Insulin Biosimilars Production by Region (2024-2029) & (K Units)
    Table 8. World Insulin Biosimilars Production Market Share by Region (2018-2023)
    Table 9. World Insulin Biosimilars Production Market Share by Region (2024-2029)
    Table 10. World Insulin Biosimilars Average Price by Region (2018-2023) & (USD/Unit)
    Table 11. World Insulin Biosimilars Average Price by Region (2024-2029) & (USD/Unit)
    Table 12. Insulin Biosimilars Major Market Trends
    Table 13. World Insulin Biosimilars Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
    Table 14. World Insulin Biosimilars Consumption by Region (2018-2023) & (K Units)
    Table 15. World Insulin Biosimilars Consumption Forecast by Region (2024-2029) & (K Units)
    Table 16. World Insulin Biosimilars Production Value by Manufacturer (2018-2023) & (USD Million)
    Table 17. Production Value Market Share of Key Insulin Biosimilars Producers in 2022
    Table 18. World Insulin Biosimilars Production by Manufacturer (2018-2023) & (K Units)
    Table 19. Production Market Share of Key Insulin Biosimilars Producers in 2022
    Table 20. World Insulin Biosimilars Average Price by Manufacturer (2018-2023) & (USD/Unit)
    Table 21. Global Insulin Biosimilars Company Evaluation Quadrant
    Table 22. World Insulin Biosimilars Industry Rank of Major Manufacturers, Based on Production Value in 2022
    Table 23. Head Office and Insulin Biosimilars Production Site of Key Manufacturer
    Table 24. Insulin Biosimilars Market: Company Product Type Footprint
    Table 25. Insulin Biosimilars Market: Company Product Application Footprint
    Table 26. Insulin Biosimilars Competitive Factors
    Table 27. Insulin Biosimilars New Entrant and Capacity Expansion Plans
    Table 28. Insulin Biosimilars Mergers & Acquisitions Activity
    Table 29. United States VS China Insulin Biosimilars Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 30. United States VS China Insulin Biosimilars Production Comparison, (2018 & 2022 & 2029) & (K Units)
    Table 31. United States VS China Insulin Biosimilars Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
    Table 32. United States Based Insulin Biosimilars Manufacturers, Headquarters and Production Site (States, Country)
    Table 33. United States Based Manufacturers Insulin Biosimilars Production Value, (2018-2023) & (USD Million)
    Table 34. United States Based Manufacturers Insulin Biosimilars Production Value Market Share (2018-2023)
    Table 35. United States Based Manufacturers Insulin Biosimilars Production (2018-2023) & (K Units)
    Table 36. United States Based Manufacturers Insulin Biosimilars Production Market Share (2018-2023)
    Table 37. China Based Insulin Biosimilars Manufacturers, Headquarters and Production Site (Province, Country)
    Table 38. China Based Manufacturers Insulin Biosimilars Production Value, (2018-2023) & (USD Million)
    Table 39. China Based Manufacturers Insulin Biosimilars Production Value Market Share (2018-2023)
    Table 40. China Based Manufacturers Insulin Biosimilars Production (2018-2023) & (K Units)
    Table 41. China Based Manufacturers Insulin Biosimilars Production Market Share (2018-2023)
    Table 42. Rest of World Based Insulin Biosimilars Manufacturers, Headquarters and Production Site (States, Country)
    Table 43. Rest of World Based Manufacturers Insulin Biosimilars Production Value, (2018-2023) & (USD Million)
    Table 44. Rest of World Based Manufacturers Insulin Biosimilars Production Value Market Share (2018-2023)
    Table 45. Rest of World Based Manufacturers Insulin Biosimilars Production (2018-2023) & (K Units)
    Table 46. Rest of World Based Manufacturers Insulin Biosimilars Production Market Share (2018-2023)
    Table 47. World Insulin Biosimilars Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 48. World Insulin Biosimilars Production by Type (2018-2023) & (K Units)
    Table 49. World Insulin Biosimilars Production by Type (2024-2029) & (K Units)
    Table 50. World Insulin Biosimilars Production Value by Type (2018-2023) & (USD Million)
    Table 51. World Insulin Biosimilars Production Value by Type (2024-2029) & (USD Million)
    Table 52. World Insulin Biosimilars Average Price by Type (2018-2023) & (USD/Unit)
    Table 53. World Insulin Biosimilars Average Price by Type (2024-2029) & (USD/Unit)
    Table 54. World Insulin Biosimilars Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 55. World Insulin Biosimilars Production by Application (2018-2023) & (K Units)
    Table 56. World Insulin Biosimilars Production by Application (2024-2029) & (K Units)
    Table 57. World Insulin Biosimilars Production Value by Application (2018-2023) & (USD Million)
    Table 58. World Insulin Biosimilars Production Value by Application (2024-2029) & (USD Million)
    Table 59. World Insulin Biosimilars Average Price by Application (2018-2023) & (USD/Unit)
    Table 60. World Insulin Biosimilars Average Price by Application (2024-2029) & (USD/Unit)
    Table 61. Sanofi S.A. Basic Information, Manufacturing Base and Competitors
    Table 62. Sanofi S.A. Major Business
    Table 63. Sanofi S.A. Insulin Biosimilars Product and Services
    Table 64. Sanofi S.A. Insulin Biosimilars Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 65. Sanofi S.A. Recent Developments/Updates
    Table 66. Sanofi S.A. Competitive Strengths & Weaknesses
    Table 67. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
    Table 68. Boehringer Ingelheim Major Business
    Table 69. Boehringer Ingelheim Insulin Biosimilars Product and Services
    Table 70. Boehringer Ingelheim Insulin Biosimilars Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 71. Boehringer Ingelheim Recent Developments/Updates
    Table 72. Boehringer Ingelheim Competitive Strengths & Weaknesses
    Table 73. Eli Lilly & Co. Basic Information, Manufacturing Base and Competitors
    Table 74. Eli Lilly & Co. Major Business
    Table 75. Eli Lilly & Co. Insulin Biosimilars Product and Services
    Table 76. Eli Lilly & Co. Insulin Biosimilars Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 77. Eli Lilly & Co. Recent Developments/Updates
    Table 78. Eli Lilly & Co. Competitive Strengths & Weaknesses
    Table 79. Novo Nordisk A/S Basic Information, Manufacturing Base and Competitors
    Table 80. Novo Nordisk A/S Major Business
    Table 81. Novo Nordisk A/S Insulin Biosimilars Product and Services
    Table 82. Novo Nordisk A/S Insulin Biosimilars Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 83. Novo Nordisk A/S Recent Developments/Updates
    Table 84. Novo Nordisk A/S Competitive Strengths & Weaknesses
    Table 85. Biocon Basic Information, Manufacturing Base and Competitors
    Table 86. Biocon Major Business
    Table 87. Biocon Insulin Biosimilars Product and Services
    Table 88. Biocon Insulin Biosimilars Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 89. Biocon Recent Developments/Updates
    Table 90. Biocon Competitive Strengths & Weaknesses
    Table 91. Geropharm Basic Information, Manufacturing Base and Competitors
    Table 92. Geropharm Major Business
    Table 93. Geropharm Insulin Biosimilars Product and Services
    Table 94. Geropharm Insulin Biosimilars Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 95. Geropharm Recent Developments/Updates
    Table 96. Geropharm Competitive Strengths & Weaknesses
    Table 97. Wockhardt Basic Information, Manufacturing Base and Competitors
    Table 98. Wockhardt Major Business
    Table 99. Wockhardt Insulin Biosimilars Product and Services
    Table 100. Wockhardt Insulin Biosimilars Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 101. Wockhardt Recent Developments/Updates
    Table 102. Wockhardt Competitive Strengths & Weaknesses
    Table 103. Gan&Lee Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 104. Gan&Lee Pharmaceuticals Major Business
    Table 105. Gan&Lee Pharmaceuticals Insulin Biosimilars Product and Services
    Table 106. Gan&Lee Pharmaceuticals Insulin Biosimilars Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 107. Gan&Lee Pharmaceuticals Recent Developments/Updates
    Table 108. Gan&Lee Pharmaceuticals Competitive Strengths & Weaknesses
    Table 109. The United Laboratories International Basic Information, Manufacturing Base and Competitors
    Table 110. The United Laboratories International Major Business
    Table 111. The United Laboratories International Insulin Biosimilars Product and Services
    Table 112. The United Laboratories International Insulin Biosimilars Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 113. The United Laboratories International Recent Developments/Updates
    Table 114. Tonghua Dongbao Pharmaceutical Basic Information, Manufacturing Base and Competitors
    Table 115. Tonghua Dongbao Pharmaceutical Major Business
    Table 116. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product and Services
    Table 117. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 118. Global Key Players of Insulin Biosimilars Upstream (Raw Materials)
    Table 119. Insulin Biosimilars Typical Customers
    Table 120. Insulin Biosimilars Typical Distributors
List of Figure
    Figure 1. Insulin Biosimilars Picture
    Figure 2. World Insulin Biosimilars Production Value: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Insulin Biosimilars Production Value and Forecast (2018-2029) & (USD Million)
    Figure 4. World Insulin Biosimilars Production (2018-2029) & (K Units)
    Figure 5. World Insulin Biosimilars Average Price (2018-2029) & (USD/Unit)
    Figure 6. World Insulin Biosimilars Production Value Market Share by Region (2018-2029)
    Figure 7. World Insulin Biosimilars Production Market Share by Region (2018-2029)
    Figure 8. North America Insulin Biosimilars Production (2018-2029) & (K Units)
    Figure 9. Europe Insulin Biosimilars Production (2018-2029) & (K Units)
    Figure 10. China Insulin Biosimilars Production (2018-2029) & (K Units)
    Figure 11. Japan Insulin Biosimilars Production (2018-2029) & (K Units)
    Figure 12. Insulin Biosimilars Market Drivers
    Figure 13. Factors Affecting Demand
    Figure 14. World Insulin Biosimilars Consumption (2018-2029) & (K Units)
    Figure 15. World Insulin Biosimilars Consumption Market Share by Region (2018-2029)
    Figure 16. United States Insulin Biosimilars Consumption (2018-2029) & (K Units)
    Figure 17. China Insulin Biosimilars Consumption (2018-2029) & (K Units)
    Figure 18. Europe Insulin Biosimilars Consumption (2018-2029) & (K Units)
    Figure 19. Japan Insulin Biosimilars Consumption (2018-2029) & (K Units)
    Figure 20. South Korea Insulin Biosimilars Consumption (2018-2029) & (K Units)
    Figure 21. ASEAN Insulin Biosimilars Consumption (2018-2029) & (K Units)
    Figure 22. India Insulin Biosimilars Consumption (2018-2029) & (K Units)
    Figure 23. Producer Shipments of Insulin Biosimilars by Manufacturer Revenue ($MM) and Market Share (%): 2022
    Figure 24. Global Four-firm Concentration Ratios (CR4) for Insulin Biosimilars Markets in 2022
    Figure 25. Global Four-firm Concentration Ratios (CR8) for Insulin Biosimilars Markets in 2022
    Figure 26. United States VS China: Insulin Biosimilars Production Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 27. United States VS China: Insulin Biosimilars Production Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Insulin Biosimilars Consumption Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. United States Based Manufacturers Insulin Biosimilars Production Market Share 2022
    Figure 30. China Based Manufacturers Insulin Biosimilars Production Market Share 2022
    Figure 31. Rest of World Based Manufacturers Insulin Biosimilars Production Market Share 2022
    Figure 32. World Insulin Biosimilars Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 33. World Insulin Biosimilars Production Value Market Share by Type in 2022
    Figure 34. Rapid-Acting Biosimilars
    Figure 35. Long-Acting Biosimilars
    Figure 36. Premixed Biosimilars
    Figure 37. World Insulin Biosimilars Production Market Share by Type (2018-2029)
    Figure 38. World Insulin Biosimilars Production Value Market Share by Type (2018-2029)
    Figure 39. World Insulin Biosimilars Average Price by Type (2018-2029) & (USD/Unit)
    Figure 40. World Insulin Biosimilars Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 41. World Insulin Biosimilars Production Value Market Share by Application in 2022
    Figure 42. Type I Diabetes
    Figure 43. Type II Diabetes
    Figure 44. World Insulin Biosimilars Production Market Share by Application (2018-2029)
    Figure 45. World Insulin Biosimilars Production Value Market Share by Application (2018-2029)
    Figure 46. World Insulin Biosimilars Average Price by Application (2018-2029) & (USD/Unit)
    Figure 47. Insulin Biosimilars Industry Chain
    Figure 48. Insulin Biosimilars Procurement Model
    Figure 49. Insulin Biosimilars Sales Model
    Figure 50. Insulin Biosimilars Sales Channels, Direct Sales, and Distribution
    Figure 51. Methodology
    Figure 52. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Sanofi S.A.
Boehringer Ingelheim
Eli Lilly & Co.
Novo Nordisk A/S
Biocon
Geropharm
Wockhardt
Gan&Lee Pharmaceuticals
The United Laboratories International
Tonghua Dongbao Pharmaceutical

Related Reports

Global Insulin Biosimilars Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Insulin Biosimilars Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

date 26 Feb 2023

date Pharma & Healthcare

Biosimilar insulin is likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulin has the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes.

Global Insulin Biosimilars Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Insulin Biosimilars Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 02 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Insulin Biosimilars market size was valued at USD 1522.8 million in 2023 and is forecast to a readjusted size of USD 1917.9 million by 2030 with a CAGR of 3.3% during review period.

Product Tags

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>